A systematic evaluation of immunoassay point-of-care testing to define impact on patients’ outcomes

Annals of Clinical Biochemistry

Volumn 54, Issue 4, 2017, Pages 420-431

  Pecoraro, Valentina ^a,b   Banfi, Giuseppe ^c,d   Germagnoli, Luca ^e   Trenti, Tommaso ^a  

^a Nuovo Ospedale S Agostino   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^e SYNLAB ACADEMY   (Germany)

Author keywords

Analytes; analytical systems; immunoassay; laboratory methods; proteins

Indexed keywords

ANTIBIOTIC AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PARATHYROID HORMONE; PROCALCITONIN; TROPONIN; CALCITONIN; LCN2 PROTEIN, HUMAN;

CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; ELECTRONIC HEALTH RECORD; HUMAN; IMMUNOASSAY; LABORATORY; MEDICAL RECORD REVIEW; PATIENT CARE; POINT OF CARE TESTING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; CLINICAL STUDY; HOSPITAL LABORATORY; METABOLISM; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTILIZATION;

C-REACTIVE PROTEIN; CALCITONIN; CLINICAL DECISION-MAKING; CLINICAL STUDIES AS TOPIC; HUMANS; IMMUNOASSAY; LABORATORIES, HOSPITAL; LIPOCALIN-2; NATRIURETIC PEPTIDE, BRAIN; PARATHYROID HORMONE; POINT-OF-CARE TESTING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TROPONIN;

EID: 85021860116     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563217694377     Document Type: Review

References (130)

1. Price CP. Point of care testing. BMJ 2001; 322: 1285–1288.
2. Altinier S, Zaninotto M, Mion MM. Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison. Clin Chem Lab Med 2006; 44: 1278–1282.
3. Pecoraro V, Germagnoli L, Banfi G. Point-of-care testing: where is the evidence? A systematic survey. Clin Chem Lab Med 2014; 52: 313–324.
4. Larsson A, Greig-Pylypczuk R, Huisman A. The state of point-of-care testing: a European perspective. Ups J Med Sci 2015; 120: 1–10.
5. Renaud B, Maison P, Ngako A. Impact of point-of-care testing in the emergency department evaluation and treatment of patients with suspected acute coronary syndromes. Acad Emerg Med 2008; 15: 216–224.
6. Asha SE, Chan AC, Walter E. Impact from point-of-care devices on emergency department patient processing times compared with central laboratory testing of blood samples: a randomised controlled trial and cost-effectiveness analysis. Emerg Med J 2014; 31: 714–719.
7. Parvin CA, Lo SF, Deuser SM. Impact of point-of-care testing on patients’ length of stay in a large emergency department. Clin Chem 1996; 42: 711–717.
8. Moher D, Liberati A, Tetzlaff J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–269, W64.
9. Alehagen U, Janzon M. A clinician’s experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting. Eur J Heart Fail 2008; 10: 260–266.
10. Clerico A, Prontera C, Emdin M. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 2005; 51: 445–447.
11. Del Ry S, Giannessi D, Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared. Clin Chem Lab Med 2001; 39: 446–450.
12. Di Somma S, Marino R, Zampini G. Predictive value for death and rehospitalization of 30-day postdischarge B-type natriuretic peptide (BNP) in elderly patients with heart failure. Sub-analysis of Italian RED Study. Clin Chem Lab Med 2015; 43: 507–513.
13. Fischer Y, Filzmaier K, Stiegler H. Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide. Clin Chem 2001; 47: 591–594.
14. Gils C, Ramanathan R, Breindahl T. NT-proBNP on Cobas h 232 in point-of-care testing: performance in the primary health care versus in the hospital laboratory. Scand J Clin Lab Invest 2015; 75: 602–609.
15. Hamilton AJ, Swales LA, Neill J. Risk stratification of chest pain patients in the emergency department by a nurse utilizing a point of care protocol. Eur J Emerg Med 2008; 15: 9–15.
16. Harrison A, Morrison LK, Krishnaswamy P. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39: 131–138.
17. Howell E, Sen S, Palmieri T. Point-of-care B-type natriuretic peptide and neutrophil gelatinase-associated lipocalin measurements for acute resuscitation: a pilot study. J Burn Care Res 2015; 36: e26–e33.
18. Khezri BS, Carlsson L, Larsson A. Evaluation of the Alere NT-proBNP test for point of care testing. J Clin Lab Anal 2016; 30: 290–292.
19. Knudsen CW, Riis JS, Finsen AV. Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: effect of age and gender. Eur J Heart Fail 2004; 6: 55–62.
20. Kosowsky JM, Weiner C, Aronson AA. Impact of point-of-care B-type natriuretic peptide (BNP) measurement on medical decision-making for older Emergency Department patients with dyspnea. J Emerg Med 2006; 31: 147–150.
21. Ishida J, Suzuki T, Aizawa K. Comparison of analytical performance of two single-step measurement devices of B-type natriuretic peptide. Int Heart J 2012; 53: 320–323.
22. Jorgensen B, Bertsch T, Broker HJ. Multicentre evaluation of a second generation point-of-care assay with an extended range for the determination of N-terminal pro-brain natriuretic peptide. Clin Lab 2012; 58: 515–525.
23. Lang NN, Wong CM, Dalzell JR. The ease of use and reproducibility of the alere™ heart check system: a comparison of patient and healthcare professional measurement of BNP. Biomark Med 2014; 8: 791–796.
24. Lee-Lewandrowski E, Januzzi JL, Green SM. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. Clin Chim Acta 2007; 386: 20–24.
25. Lepoutre T, Rousseau MF, Ahn SA. Measurement Nt-proBNP circulating concentrations in heart failure patients with a new point-of-care assay. Clin Lab 2013; 59: 831–835.
26. Olausson J, Petersonl C, Bergstrom M. Evaluation of the meritas® BNP test for point-of-care testing. Clin Lab 2015; 61: 727–730.
27. Prontera C, Storti S, Emdin M. Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. Clin Lab 2005; 51: 1274–1276.
28. Prontera C, Masotti S, Franzini M. Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform. Clin Chem Lab Med 2015; 53: e125–e127.
29. Prosen G, Klemen P, Strnad M. Combination of lung ultrasound (a comet-tail sign) and N-terminal pro-brain natriuretic peptide in differentiating acute heart failure from chronic obstructive pulmonary disease and asthma as cause of acute dyspnea in prehospital emergency setting. Crit Care 2011; 15: R114–R114.
30. Ro R, Thode HC, Jr Taylor M. Comparison of the diagnostic characteristics of two B-type natriuretic peptide point-of-care devices. J Emerg Med 2011; 41: 661–667.
31. Shah K, Terracciano GJ, Jiang K. Comparability of Results between Point-of-care and automated instruments to measure B-type natriuretic peptide. West J Emerg Med 2010; 11: 44–48.
32. Tjeerdsma G, de Boer RA, Boomsma F. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2002; 86: 143–149. discussion 9–52.
33. Verdú JM, Comín-Colet J, Domingo M. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care. Rev Esp Cardiol 2012; 65: 613–619.
34. Vogeser M, Jacob K. B-type natriuretic peptide (BNP) – validation of an immediate response assay. Clin Lab 2001; 47: 29–33.
35. Wei T, Zeng C, Chen L. Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail 2005; 7: 75–79.
36. Wieczorek SJ, Wu AH, Christenson R. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002; 144: 834–839.
37. Wu Z, Zhao M, He M. Validation of the use of B-type natriuretic peptide point-of-care test platform in preliminary recognition of cardioembolic stroke patients in the ED. Am J Emerg Med 2015; 33: 521–526.
38. Zaninotto M, Mion MM, Di Serio F. PATHFAST™ NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay. Clin Chem Lab Med 2010; 48: 1029–1034.
39. Zugck C, Nelles M, Katus HA. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clin Chem Lab Med 2006; 44: 1269–1277.
40. Andreeva E, Melbye H. Usefulness of C-reactive protein testing in acute cough/respiratory tract infection: an open cluster-randomized clinical trial with C-reactive protein testing in the intervention group. BMC Fam Pract 2014; 15: 80–80.
41. Aydin B, Dilli D, Zenciroglu A. Comparison of a rapid bed-side test with a central laboratory analysis for C-reactive protein in newborn infants with suspicion of sepsis. Clin Lab 2013; 59: 1045–1051.
42. Brouwer N, van Pelt J. Validation and evaluation of eight commercially available point of care CRP methods. Clin Chim Acta 2015; 439: 195–201.
43. Cals JW, Schot MJ, de Jong SA. Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Ann Fam Med 2010; 8: 124–133.
44. Cals JWL, Ament AJHA, Hood K. C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. J Eval Clin Pract 2011; 17: 1059–1069.
45. Dahler-Eriksen BS, Lauritzen T, Lassen JF. Near-patient test for C-reactive protein in general practice: assessment of clinical, organizational, and economic outcomes. Clin Chem 1999; 45: 478–485.
46. Diar HA, Nakwa FL, Thomas R. Evaluating the QuikRead® C-reactive protein test as a point-of-care test. Paediatr Int Child Health 2012; 32: 35–42.
47. Esposito S, Tremolati E, Begliatti E. Evaluation of a rapid bedside test for the quantitative determination of C-reactive protein. Clin Chem Lab Med 2005; 43: 438–440.
48. Gonzales R, Aagaard EM, Camargo CA, Jr. C-reactive protein testing does not decrease antibiotic use for acute cough illness when compared to a clinical algorithm. J Emerg Med 2011; 41: 1–7.
49. Jakobsen KA, Melbye H, Kelly MJ. Influence of CRP testing and clinical findings on antibiotic prescribing in adults presenting with acute cough in primary care. Scand J Prim Health Care 2010; 28: 229–236.
50. Lindstrom J, Nordeman L, Hagstrom B. What a difference a CRP makes. A prospective observational study on how point-of-care C-reactive protein testing influences antibiotic prescription for respiratory tract infections in Swedish primary health care. Scand J Prim Health Care 2015; 33: 275–282.
51. Marcus N, Mor M, Amir L. The Quick-Read C-reactive protein test for the prediction of bacterial gastroenteritis in the pediatric emergency department. Pediatr Emerg Care 2007; 23: 634–637.
52. Marcus N, Mor M, Amir L. Validity of the quick-read C-reactive protein test in the prediction of bacterial pneumonia in the pediatric emergency department. Eur J Emerg Med 2008; 15: 158–161.
53. Markovic S, Armbruster FP, Dschietzig TB. Comparison of a point-of-care test for high-sensitivity C-reactive protein with an established immuno-nephelometric method. Clin Lab 2015; 61: 1585–1588.
54. Minnaard MC, Van De Pol AC, Broekhuizen BDL. Analytical performance, agreement and user-friendliness of five C-reactive protein point-of-care tests. Scand J Clin Lab Invest 2013; 73: 627–634.
55. Minnaard MC, Van De Pol AC, De Groot JAH. The added diagnostic value of five different C-reactive protein point-of-care test devices in detecting pneumonia in primary care: a nested case-control study. Scand J Clin Lab Invest 2015; 75: 291–295.
56. Monteny M, Ten Brinke MH, Van Brakel J. Point-of-care C-reactive protein testing in febrile children in general practice. Clin Chem Lab Med 2006; 44: 1428–1432.
57. Oh SW, Moon JD, Park SY. Evaluation of fluorescence hs-CRP immunoassay for point-of-care testing. Clin Chim Acta 2005; 356: 172–177.
58. Papa F, Rongioletti M, Majolini MB. Fast bedside measurement of blood count and C-reactive protein in newborns compared with conventional methods. Clin Lab 2012; 58: 951–957.
59. Peters CM, Schouwenaars FM, Haagsma E. Antibiotic prescribing and C-reactive protein testing for pulmonary infections in patients with intellectual disabilities. Br J Gen Pract 2013; 63: e326–e330.
60. Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection. Eur Clin Respir J 2015; 2: 28245–28245.
61. Seamark DA, Backhouse SN, Powell R. Field-testing and validation in a primary care setting of a point-of-care test for C-reactive protein. Ann Clin Biochem 2003; 40: 178–180.
62. Siebenhaar R, Mushholt PB, Forst T. Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation. J Diabetes Sci Technol 2010; 4: 717–722.
63. Van den Bruel A, Jones C, Thompson M. C-reactive protein point-of-care testing in acutely ill children: a mixed methods study in primary care. Arch Dis Child 2016; 101: 382–385.
64. Yebyo H, Medhanyie AA, Spigt M. C-reactive protein point-of-care testing and antibiotic prescribing for acute respiratory tract infections in rural primary health centres of North Ethiopia: a cross-sectional study. NPJ Prim Care Respir Med 2016; 26: 15076–15076.
65. De Berardinis B, Gaggin H, Magrini L. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. Clin Chem Lab Med 2015; 53: 613–621.
66. Dent CL, Ma Q, Dastrala S. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 2007; 11: R127–R127.
67. Di Somma S, Magrini L, De Berardinis B. Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care 2013; 17: R29–R29.
68. Hollmen ME, Kyllönen LE, Merenmies J. Serum neutrophil gelatinase-associated lipocalin and recovery of kidney graft function after transplantation. BMC Nephrol 2014; 15: 123–123.
69. Hur M, Kim H, Lee S. Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. BMC Infect Dis 2014; 14: 224–224.
70. Kutz A, Hausfater P, Oppert M. Comparison between B.R.A.H.M.S PCT direct, a new sensitive point-of-care testing device for rapid quantification of procalcitonin in emergency department patients, and established reference methods – a prospective multinational trial. Clin Chem Lab Med 2016; 54: 577–584.
71. Meisner M, Brunkhorst FM, Reith HB. Clinical experiences with a new semi-quantitative solid phase immunoassay for rapid measurement of procalcitonin. Clin Chem Lab Med 2000; 38: 989–995.
72. Agarwal G, Barakate MS, Robinson B. Intraoperative quick parathyroid hormone versus same-day parathyroid hormone testing for minimally invasive parathyroidectomy: a cost-effectiveness study. Surgery 2001; 130: 963–970.
73. Carneiro DM, Irvin GL, 3rd. New point-of-care intraoperative parathyroid hormone assay for intraoperative guidance in parathyroidectomy. World J Surg 2002; 26: 1074–1077.
74. Farrag T, Weinberger P, Seybt M. Point-of-care rapid intraoperative parathyroid hormone assay of needle aspirates from parathyroid tissue: a substitute for frozen sections. Am J Otolaryngol 2011; 32: 574–577.
75. Johnson LR, Doherty G, Lairmore T. Evaluation of the performance and clinical impact of a rapid intraoperative parathyroid hormone assay in conjunction with preoperative imaging and concise parathyroidectomy. Clin Chem 2001; 47: 919–925.
76. Sokoll LJ, Drew H, Udelsman R. Intraoperative parathyroid hormone analysis: a study of 200 consecutive cases. Clin Chem 2000; 46: 1662–1668.
77. Terris DJ, Weinberger PM, Farrag T. Restoring point-of-care testing during parathyroidectomy with a newer parathyroid hormone assay. Otolaryngology 2011; 145: 557–560.
78. Aldous S, Mark Richards A, George PM. Comparison of new point-of-care troponin assay with high sensitivity troponin in diagnosing myocardial infarction. Int J Cardiol 2014; 177: 182–186.
79. Andersson PO, Karlsson JE, Landberg E. Consequences of high-sensitivity troponin T testing applied in a primary care population with chest pain compared with a commercially available point-of-care troponin T analysis: an observational prospective study. BMC Res Notes 2015; 8: 210–210.
80. Apple FS, Murakami MM, Christenson RH. Analytical performance of the i-STAT cardiac troponin I assay. Clin Chim Acta 2004; 345: 123–127.
81. Apple FS, Ler R, Chung AY. Point-of-care i-STAT cardiac troponin I for assessment of patients with symptoms suggestive of acute coronary syndrome. Clin Chem 2006; 52: 322–325.
82. Asha SE, Cooke A, Walter E. Three-month outcome of patients with suspected acute coronary syndrome using point-of-care cardiac troponin-T testing compared with laboratory-based cardiac troponin-T testing: a randomised trial. Emerg Med J 2015; 32: 601–607.
83. Birkhahn RH, Haines E, Wen W. Estimating the clinical impact of bringing a multimarker cardiac panel to the bedside in the ED. Am J Emerg Med 2011; 29: 304–308.
84. Blick KE. The benefits of a rapid, point-of-care “TnI-Only” zero and 2-hour protocol for the evaluation of chest pain patients in the emergency department. Clin Lab Med 2014; 34: 75–85.
85. Bock JL, Singer AJ, Thode HC, Jr. Comparison of emergency department patient classification by point-of-care and central laboratory methods for cardiac troponin I. Am J Clin Pathol 2008; 130: 132–135.
86. Collinson PO, Jørgensen B, Sylvén C. Recalibration of the point-of-care test for CARDIAC T quantitative with Elecsys troponin T 3rd generation. Clin Chim Acta 2001; 307: 197–203.
87. Collinson PO, John C, Lynch S. A prospective randomized controlled trial of point-of-care testing on the coronary care unit. Ann Clin Biochem 2004; 41: 397–404.
88. Collinson P, Goodacre S, Gaze D. Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial. Heart 2012; 98: 312–318.
89. Cramer GE, Kievit PC, Brouwer MA. Lack of concordance between a rapid bedside and conventional laboratory method of cardiac troponin testing: impact on risk stratification of patients suspected of acute coronary syndrome. Clin Chim Acta 2007; 381: 164–166.
90. Diercks DB, Peacock Iv WF, Hollander JE. Diagnostic accuracy of a point-of-care troponin i assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain. Am Heart J 2012; 163: 74–80.e4.
91. Di Serio F, Amodio G, Varraso L. Integration between point-of-care cardiac markers in an emergency/cardiology department and the central laboratory: methodological and preliminary clinical evaluation. Clin Chem Lab Med 2005; 43: 202–209.
92. Dupuy AM, Sebbane M, Roubille F. Analytical evaluation of point of care cTnT and clinical performances in an unselected population as compared with central laboratory highly sensitive cTnT. Clin Biochem 2015; 48: 334–339.
93. Ezekowitz JA, Welsh RC, Weiss D. Providing Rapid out of hospital acute cardiovascular treatment 4 (PROACT-4). J Am Heart Assoc 2015; 4: e002859–e002859.
94. Farsi D, Pishbin E, Abbasi S. Operating characteristics of a qualitative troponin assay for the diagnosis of acute coronary syndrome. Eur J Emerg Med 2013; 20: 120–122.
95. Goldmann BU, Langenbrink L, Matschuck G. Quantitative bedside testing of troponin T: is it equal to laboratory testing? The cardiac reader troponin T (CARE T) study. Clin Lab 2004; 50: 1–10.
96. Goodacre SW, Bradburn M, Cross E. The randomised assessment of treatment using panel assay of cardiac markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011; 97: 190–196.
97. Hallani H, Leung DY, Newland E. Use of a quantitative point-of-care test for the detection of serum cardiac troponin T in patients with suspected acute coronary syndromes. Intern Med J 2005; 35: 560–562.
98. Heeschen C, Goldmann BU, Moeller RH. Analytical performance and clinical application of a new rapid bedside assay for the detection of serum cardiac troponin I. Clin Chem 1998; 44: 1925–1930.
99. Heeschen C, Goldmann BU, Langenbrink L. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem 1999; 45: 1789–1796.
100. Hjortshøj S, Venge P, Ravkilde J. Clinical performance of a new point-of-care cardiac troponin I assay compared to three laboratory troponin assays. Clin Chim Acta 2011; 412: 370–375.
101. Lee-Lewandrowski E, Januzzi JL, Grisson R. Evaluation of first-draw whole blood, point-of-care cardiac markers in the context of the universal definition of myocardial infarction: a comparison of a multimarker panel to troponin alone and to testing in the central laboratory. Arch Pathol Lab Med 2011; 135: 459–463.
102. Loten C, Attia J, Hullick C. Validation of a point of care troponin assay in real life emergency department conditions. EMA 2009; 21: 286–292.
103. Loten C, Attia J, Hullick C. Point of care troponin decreases time in the emergency department for patients with possible acute coronary syndrome: a randomised controlled trial. Emerg Med J 2010; 27: 194–198.
104. McCord J, Nowak RM, McCullough PA. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001; 104: 1483–1488.
105. Muller-Bardorff M, Rauscher T, Kampmann M. Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing. Clin Chem 1999; 45: 1002–1008.
106. Monneret D, Abbes RAB, Omarjee R. Analytical comparison of the new point-of-care troponin T immunoassay on AQT90Flex® analyzer (Radiometer) and the high-sensitivity troponin T immunoassay on ModularE170® (Roche Diagnostics). Clin Chem Lab Med 2014; 52: e279–e282.
107. Ng SM, Krishnaswamy P, Morissey R. Ninety-minute accelerated critical pathway for chest pain evaluation. Am J Cardiol 2001; 88: 611–617.
108. Nilsson S, Andersson PO, Borgquist L. Point-of-care troponin T testing in the management of patients with chest pain in the Swedish primary care. Int J Family Med 2013; 2013: 532093–532093.
109. Ohman EM, Armstrong PW, White HD. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global use of strategies to open occluded coronary arteries. Am J Cardiol 1999; 84: 1281–1286.
110. Ordóñez-Llanos J, Santaló-Bel M, Mercé-Muntañola J. Risk stratification of chest pain patients by point-of-care cardiac troponin T and myoglobin measured in the emergency department. Clin Chim Acta 2006; 365: 93–97.
111. Palamalai V, Murakami MM, Apple FS. Diagnostic performance of four point of care cardiac troponin I assays to rule in and rule out acute myocardial infarction. Clin Biochem 2013; 46: 1631–1635.
112. Baxter MS, Brogan GX, Harchelroad FP. Evaluation of a bedside whole-blood rapid troponin T assay in the emergency department. Rapid Evaluation by Assay of Cardiac Troponin T (REACTT) Investigators Study Group. Acad Emerg Med 1997; 4: 1018–1024.
113. Schneider HG, Ablitt P, Taylor J. Improved sensitivity of point of care troponin I values using reporting to below the 99th percentile of normals. Clini Biochem 2013; 46: 979–982.
114. Schuchert A, Hamm C, Scholz J. Prehospital testing for troponin T in patients with suspected acute myocardial infarction. Am Heart J 1999; 138: 45–48.
115. Stengaard C, Sørensen JT, Ladefoged SA. Quantitative point-of-care troponin T measurement for diagnosis and prognosis in patients with a suspected acute myocardial infarction. Am J Cardiol 2013; 112: 1361–1366.
116. Sørensen JT, Terkelsen CJ, Steengaard C. Prehospital troponin T testing in the diagnosis and triage of patients with suspected acute myocardial infarction. Am J Cardiol 2011; 107: 1436–1440.
117. ter Avest E, Visser A, Reitsma B. Point-of-care troponin T is inferior to high-sensitivity troponin T for ruling out acute myocardial infarction in the emergency department. Eur J Emerg Med 2016; 23: 95–101.
118. Tomonaga Y, Gutzwiller F, Lüscher TF. Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial. BMC Fam Pract 2011; 12: 12–12.
119. Venge P, Öhberg C, Flodin M. Early and late outcome prediction of death in the emergency room setting by point-of-care and laboratory assays of cardiac troponin I. Am Heart J 2010; 160: 835–841.
120. Wu AHB, Smith A, Christenson RH. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Clin Chim Acta 2004; 346: 211–219.
121. Huang Y, Chen R, Wu T. Association between point-of-care CRP testing and antibiotic prescribing in respiratory tract infections: a systematic review and meta-analysis of primary care studies. Br J Gen Pract 2013; 63: e787–e794.
122. Bingisser R, Cairns C, Christ M. Cardiac troponin: a critical review of the case for point-of-care testing in the ED. Am J Emerg Med 2012; 30: 1639–1649.
123. Collinson PO. The need for a point of care testing: an evidence-based appraisal. Scand J Clin Lab Invest Suppl 1999; 59: 67–73.
124. Di Somma S, Zampini G, Vetrone F. Opinion paper on utility of point-of-care biomarkers in the emergency department pathways decision making. Clin Chem Lab Med 2014; 52: 1401–1407.
125. Storrow AB, Lyon J, Porter M. A systematic review of emergency department point-of-care cardiac markers and efficiency measures. ùpoint Care 2009; 8: 121–125.
126. Grodzinsky E, Wirehn AB, Fremner E. Point-of-care testing has a limited effect on time to clinical decision in primary health care. Scand J Clin Lab Invest 2004; 64: 547–551.
127. Mogensen CB, Borch A, Brandslund I. Point of care technology or standard laboratory service in an emergency department: is there a difference in time to action? A randomised trial. Scand J Trauma Resusc Emerg Med 2011; 19: 49–49.
128. Kendall J, Reeves B, Clancy M. Point of care testing: randomised controlled trial of clinical outcome. BMJ 1998; 316: 1052–1057.
129. Brock TK, Mecozzi DM, Sumner S. Evidence-based point-of-care tests and device designs for disaster preparedness. Am J Disaster Med 2010; 5: 285–294.
130. Drain PK, Hyle EP, Noubary F. Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis 2014; 14: 239–249.